NASDAQ$SNDX
Syndax Pharmaceuticals Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Syndax reported financial results and provided a clinical and business update.
Syndax Pharmaceuticals reported its Q3 2021 financial results, highlighting the initiation of the pivotal Phase 2 portion of the SNDX-5613 AUGMENT-101 trial and a global collaboration with Incyte for axatilimab. Updated data from SNDX-5613 and axatilimab clinical programs will be presented at the ASH Annual Meeting.
- Pivotal Phase 2 portion of SNDX-5613 AUGMENT-101 trial was initiated in patients with NPM1 and MLLr acute leukemias.
- Global collaboration with Incyte was entered to develop and commercialize axatilimab for cGVHD and other fibrotic diseases.
- Updated data from SNDX-5613 and axatilimab clinical programs will be presented at the 63rd ASH Annual Meeting.
- A new trial to assess the anti-leukemic efficacy of SNDX-5613 in NPM1 or MLLr patients with measurable residual disease (MRD) progression following initial treatment planned.
Headline financials
Revenue & EPS history
Syndax · Revenue · Quarterly
$12.4M
Revenue by segment
Syndax · $38M total across 2 segments · Q2 2025
- Revuforj (product)$28.6M—75.3%
- Niktimvo (collaboration)$9.36M—24.7%
Forward guidance
Syndax provided financial guidance for the full year of 2021.
Tailwinds
- R&D expenses are expected to be $90 to $100 million.
- Total operating expenses are expected to be $110 to $120 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2021
+1.6%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+3.5%
Avg return
30 days after
60%
24 / 40 earnings
Positive
+15.1%
Q4 2019
Best reaction
-21.6%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +3.9% | -2.6% | -5.2% | |
| Q4 2025 | +5.1% | +4.6% | +13.6% | |
| Q3 2025 | +11.6% | +9.3% | +43.5% | |
| Q1 2025 | -21.6% | -21.1% | -17.8% | |
| Q4 2024 | -7.1% | -13.3% | -19.5% | |
| Q3 2024 | +12.7% | +15.2% | -11.3% | |
| Q2 2024 | -7.3% | -12.3% | -9.5% | |
| Q1 2024 | -5.2% | -9.5% | -15.9% | |
| Q4 2023 | -2.1% | -2.7% | -2.4% | |
| Q3 2023 | +6.3% | +5.0% | +19.0% | |
| Q2 2023 | -3.5% | -10.9% | -4.5% | |
| Q1 2023 | +7.8% | +5.0% | +3.8% | |
| Q4 2022 | +1.6% | -0.1% | -15.6% | |
| Q3 2022 | -2.0% | -2.2% | +9.5% | |
| Q2 2022 | +0.5% | +0.5% | -2.4% | |
| Q1 2022 | -5.8% | -12.3% | +10.1% | |
| Q4 2021 | +3.3% | -2.2% | +11.5% | |
| Q3 2021 | +2.1% | -0.9% | +5.9% | |
| Q2 2021 | +7.0% | +11.2% | +23.9% | |
| Q1 2021 | +14.6% | +18.5% | +21.5% | |
| Q4 2020 | +0.4% | -2.8% | -5.3% | |
| Q3 2020 | +8.8% | +20.4% | +30.9% | |
| Q2 2020 | +6.5% | -0.9% | +0.7% | |
| Q1 2020 | -1.8% | +3.2% | -8.0% | |
| Q4 2019 | +15.1% | +22.8% | -0.6% | |
| Q3 2019 | -0.3% | +0.3% | +24.5% | |
| Q2 2019 | +10.6% | +8.6% | -3.0% | |
| Q1 2019 | +9.1% | +6.1% | +3.9% | |
| Q4 2018 | -13.5% | -11.1% | -4.2% | |
| Q3 2018 | +2.1% | +5.9% | -3.5% | |
| Q2 2018 | +12.0% | +6.7% | +8.8% | |
| Q1 2018 | +9.9% | +1.5% | -25.5% | |
| Q4 2017 | -1.5% | -0.6% | +47.9% | |
| Q3 2017 | -11.7% | -10.1% | -28.4% | |
| Q2 2017 | -5.7% | -1.5% | +8.0% | |
| Q1 2017 | -7.0% | +4.7% | +26.7% | |
| Q4 2016 | +5.0% | +1.0% | +18.0% | |
| Q3 2016 | +0.9% | -4.9% | -17.1% | |
| Q2 2016 | +5.6% | +5.5% | +3.1% | |
| Q1 2016 | -2.1% | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro